Article written by Marian Monroe.
Q-Centrix, the nation’s leading provider of clinical data management solutions, has made significant strides with its Research Network since its inception in 2023. Designed to connect hospitals with greater access to sponsored clinical research opportunities, the Q-Centrix Research Network is rapidly transforming the landscape of clinical trials in the U.S.
The network, which is part of Q-Centrix’s innovative approach to healthcare, invites participation from hospital partners seeking to enhance research opportunities for their communities. Simultaneously, it caters to life sciences organizations aiming to identify appropriate patient populations for clinical trials and studies—addressing long-standing challenges within the clinical research ecosystem.
With a footprint in over 1,200 hospitals and health systems, Q-Centrix recognized an urgent need to connect hospitals with limited access to clinical research with pharmaceutical companies struggling to find diverse patient populations. This gap is particularly impactful considering the staggering statistic shared by Victor Wang, Senior Vice President of Data & Research at Q-Centrix: “Two-thirds of all clinical trials fail to enroll enough patients for an effective study.”
Wang emphasized the critical importance of expanding trial accessibility, especially in underserved communities where diversity in research is often limited. “The lack of diversity in so many of today’s clinical trials is due to recruitment limitations,” Wang explained. “This is a challenge we aim to address by connecting the right patients with the right studies.”
In just over a year, the Q-Centrix Research Network has grown into a vital resource for healthcare organizations across the country. Members include prominent health systems and hospitals such as Bon Secours Mercy Health, Carle Health, Tampa General Hospital, John Muir Health, Renown Health, Onvida Health (formerly Yuma Regional Medical Center), Baptist Health Care, Summa Health, Tucson Medical Center, and Kootenai Health. Together, these members serve over 1.26 million patients, significantly expanding the reach of clinical research into diverse communities.
Membership is not limited to large hospital networks; the Research Network also supports individual facilities, including those in areas with underserved populations. For many of these communities, participating in clinical research was previously an infrequent opportunity. Q-Centrix is working to change that by embedding clinical trials as a standard of care.
Through partnerships with member hospitals, Q-Centrix is enabling a range of pharmaceutical engagements. These include building tailored data sets for retrospective studies and assisting hospitals with patient pre-screening for sponsored clinical trials. Such initiatives not only streamline the research process but also empower hospitals to take a more active role in groundbreaking medical advancements.
Wang highlighted the strategic value of the network’s approach: “We are just at the beginning of building the bridges between hospitals and research. The idea has always been there, but the infrastructure, or more precisely, a company with the experience to provide the infrastructure, has not.”
By providing this infrastructure, Q-Centrix is helping hospitals unlock new funding sources and extract greater value from their clinical data. This dual benefit enhances the financial and operational sustainability of healthcare institutions while advancing patient care through research.
One of the most transformative aspects of the Q-Centrix Research Network is its focus on inclusivity. The network prioritizes collaboration with hospitals serving populations that have historically been underrepresented in clinical trials. This approach ensures that more individuals have access to potentially life-saving treatments and contributes to a more comprehensive understanding of how treatments perform across different demographics.
“Hospitals in underserved areas are often overlooked by research initiatives,” Wang said. “By connecting these facilities with sponsored studies, we’re not only providing them with additional resources but also helping address the disparities in clinical research.”
The rapid growth of the Q-Centrix Research Network illustrates a broader shift in the healthcare industry. Hospitals and health systems are increasingly recognizing the value of participating in clinical research, not just as a means of enhancing their services but as a critical component of advancing medical science.
The network’s success also underscores the growing demand for a more patient-centric approach to clinical trials. By addressing the logistical and systemic barriers that have historically hindered participation, Q-Centrix is paving the way for a new era where clinical trials are more accessible, equitable, and effective.
Looking forward, Q-Centrix is poised to continue its momentum in reshaping clinical research accessibility. The company remains committed to expanding its network, forging new partnerships, and refining its processes to better serve hospitals, life sciences organizations, and, most importantly, patients.
“The work we’re doing is just the beginning,” Wang concluded. “We’re building the infrastructure that will make clinical trials a standard part of care in every community. It’s an ambitious goal, but it’s one we’re deeply passionate about achieving.”
As the Q-Centrix Research Network grows, it offers a glimpse into the future of clinical research—one where collaboration, innovation, and inclusivity come together to drive medical progress and improve patient outcomes. By addressing the gaps in clinical trial accessibility and diversity, Q-Centrix is not only transforming the research landscape but also ensuring that advancements in healthcare reach those who need them most.